CHEK2 and breast carcinoma: Although our results differ from previous studies in CHEK2 c.1100delC breast cancer patients, one recent study in breast cancer patients with any (likely) pathogenic CHEK2 variants also showed a similar breast cancer-specific survival in heterozygotes and non-carriers [25].